Model exl01 - Single Bacterial Strain Drug

Our research has led us to discover that patients suffering from inflammatory bowel diseases lack a crucial bacterium and, therefore, do not have a fair chance to fight their conditions. We have developed a single bacterial strain drug candidate to deliver the key bacteria Faecalibacterium praustnizii for the treatment of inflammatory bowel diseases, starting with Crohn`s Disease as a first indication.